NICE has issued a final appraisal determination recommending Celgene's Otezla for adults with active psoriatic arthritis, reversing an earlier decision to reject the drug. The oral drug is Celgene ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase ... or younger and that there was no active comparator.

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for all the estimated eight ...

The usual maintenance dosage of Otezla (apremilast) is two 30-mg doses per day. It’s important to take the Otezla dosage your doctor prescribes. Otezla belongs to a class of drugs called disease ...

Icotrokinra is being studied in the pivotal Phase 3 ICONIC clinical development program in moderate-to-severe plaque psoriasis and active psoriatic arthritis and the Phase 2b ANTHEM-UC study in ...

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

2025SELARSDI is approved for all indications matching the reference productSELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults ...

How psoriasis affects your skin and nails when you have psoriatic arthritis may be different than if you have psoriasis alone. For most people living with psoriatic arthritis (PsA), psoriasis is also ...